Lefamulin, a recently approved novel antibacterial agent to fight against community-acquired bacterial pneumonia
Main Authors: | Shouvik Choudhury, Moumita Bala, Dwaipayan Sarathi Chakraborty, Sandeep Lahiry |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Lung India |
Online Access: | http://www.lungindia.com/article.asp?issn=0970-2113;year=2021;volume=38;issue=3;spage=300;epage=301;aulast=Choudhury |
Similar Items
-
Osimertinib as an emerging therapeutic modality in nonsmall cell lung cancer: Opportunities and challenges in Indian scenario
by: Sayanta Thakur, et al.
Published: (2020-01-01) -
Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities
by: Thomas M. File, et al.
Published: (2021-05-01) -
Polymyxin B-Induced Diffuse Cutaneous Hyperpigmentation
by: Sandeep Lahiry, et al.
Published: (2017-02-01) -
Effect of 1,25 dihydroxy vitamin D3 supplementation on pain relief in early rheumatoid arthritis
by: Dibyendu Mukherjee, et al.
Published: (2019-01-01) -
MODERN ANTIBACTERIAL THERAPY IN HOSPITAL-ACQUIRED PNEUMONIA
by: V. B. Beloborodov, et al.
Published: (2017-11-01)